Table of Contents
Joint Meeting Transmissible Spongiform Encephalopathies & Blood Products Advisory Committees January 17, 2001 Effectiveness of measures taken to protect humans from food-borne exposure to the BSE agent: Implications for risk of variant Creutzfeldt-Jakob disease and blood safety
Issue
Approaches to Remote or Theoretical Risks of Contamination in Regulated Products
History of FDA Guidances on Precautionary Measures to Reduce Possible Risk of Transmission of Creutzfeldt-Jakob Disease & Variant Creutzfeldt-Jakob Disease by Blood & Blood Products
History of FDA Guidances on CJD/vCJD regarding Blood and Blood Products
History of FDA Guidances on CJD/vCJD regarding Blood and Blood Products
FDA Revised Guidance on CJD/vCJD & Blood Jan 2002: Estimated Reduction in Risk-adjusted Donor Days after Implementation (A. Williams, OBRR, CBER, FDA)
18 Countries with BSE in Native Cattle [yr first reported & approx. total cases through 2001 per OIE Dec 2001]
Measures thought to be effective in protecting humans from food-borne exposures to BSE agent
Measures thought to be effective in protecting humans from food-borne exposures to BSE agent
Measures thought to be effective in protecting humans from food-borne exposures to BSE agent
Measures thought to be effective in protecting humans from food-borne exposures to the BSE agent
Measures thought to be effective in protecting humans from food-borne exposures to the BSE agent
Charge
Question 1
Question 2
Question 3
PPT Slide
|
Author: David M. Asher, MD
|